- Home
- AVD vs SLS Comparison
AVD vs SLS Comparison
Compare AVD & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVD
- SLS
- Stock Information
- Founded
- AVD 1969
- SLS 2012
- Country
- AVD United States
- SLS United States
- Employees
- AVD N/A
- SLS N/A
- Industry
- AVD Agricultural Chemicals
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- AVD Industrials
- SLS Health Care
- Exchange
- AVD Nasdaq
- SLS Nasdaq
- Market Cap
- AVD 158.9M
- SLS 185.3M
- IPO Year
- AVD N/A
- SLS N/A
- Fundamental
- Price
- AVD $5.61
- SLS $1.85
- Analyst Decision
- AVD Strong Buy
- SLS Strong Buy
- Analyst Count
- AVD 1
- SLS 1
- Target Price
- AVD $12.00
- SLS $7.00
- AVG Volume (30 Days)
- AVD 165.0K
- SLS 1.9M
- Earning Date
- AVD 11-10-2025
- SLS 11-12-2025
- Dividend Yield
- AVD N/A
- SLS N/A
- EPS Growth
- AVD N/A
- SLS N/A
- EPS
- AVD N/A
- SLS N/A
- Revenue
- AVD $529,067,000.00
- SLS N/A
- Revenue This Year
- AVD N/A
- SLS N/A
- Revenue Next Year
- AVD $3.54
- SLS N/A
- P/E Ratio
- AVD N/A
- SLS N/A
- Revenue Growth
- AVD N/A
- SLS N/A
- 52 Week Low
- AVD $3.28
- SLS $0.77
- 52 Week High
- AVD $6.68
- SLS $2.27
- Technical
- Relative Strength Index (RSI)
- AVD 62.42
- SLS 52.67
- Support Level
- AVD $5.24
- SLS $1.69
- Resistance Level
- AVD $5.84
- SLS $2.01
- Average True Range (ATR)
- AVD 0.25
- SLS 0.11
- MACD
- AVD -0.03
- SLS 0.00
- Stochastic Oscillator
- AVD 70.13
- SLS 50.00
About AVD American Vanguard Corporation ($0.10 Par Value)
American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.